{"canonical":"https://abierto.us/opportunities/36e79727q0001","key":"36E79727Q0001","url":"https://abierto.us/opportunities/36e79727q0001","title":"6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028","solicitation_number":"36E79727Q0001","notice_type":"r","open":true,"removed":false,"removed_at":null,"response_deadline":"2026-11-16T17:00:00Z","first_posted":"2026-11-02","last_posted":"2026-11-02","department":"VETERANS AFFAIRS, DEPARTMENT OF","subagency":"VETERANS AFFAIRS, DEPARTMENT OF","office":"NAC PRIME VENDOR (36W797)","naics":"325412","psc":"6505","set_aside":null,"place_state":null,"place_scope":"nationwide","site":null,"place_state_source":null,"place_evidence":"Product purchase (PSC 6505)","place_county":null,"place_county_name":null,"place_city":null,"place_city_name":null,"winner":null,"award_amount":null,"publications":[{"notice_id":"b02e003de86144c7b12c4c0b7801aab5","title":"6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028","solicitation_number":"36E79727Q0001","notice_type":"r","base_type":"r","posted":"2026-11-02","posted_at":"2026-11-02T17:00:15.329Z","due_at":"2026-11-16T17:00:00Z","due_date":"2026-11-16","cancelled":false,"archived":false,"archive_date":"2027-01-15","removed_at":null,"award_number":null,"awardee_name":null,"amount":null,"link_sam":"https://sam.gov/workspace/contract/opp/b02e003de86144c7b12c4c0b7801aab5/view","enriched":true,"history":[{"index":1,"title":"6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028","action":"publish","latest":true,"deleted":false,"archived":false,"cancelled":false,"posted_at":"2026-11-02T17:00:15.329Z","notice_type":{"code":"r","label":"Sources Sought"},"request_type":"submit","opportunity_id":"b02e003de86144c7b12c4c0b7801aab5","solicitation_number":"36E79727Q0001"}]}],"latest_notice_id":"b02e003de86144c7b12c4c0b7801aab5","first_type":"r","notices":[{"award":{"awardee":{}},"dates":{"posted":"2026-11-02","posted_at":"2026-11-02T17:00:15.329Z","created_at":"2026-11-02T17:00:13.129Z","modified_at":"2026-11-02T17:00:15.329Z","response_deadline":{"raw":"2026-11-16T11:00:00-06:00","utc":"2026-11-16T17:00:00Z","date":"2026-11-16","time":"11:00:00","timezone":"America/Chicago","utc_offset_seconds":-21600}},"links":{"sam":"https://sam.gov/workspace/contract/opp/b02e003de86144c7b12c4c0b7801aab5/view"},"naics":{"codes":["325412"],"primary":"325412"},"title":"6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028","agency":{"office":{"code":"36W797","name":"NAC PRIME VENDOR (36W797)"},"subtier":{"code":"3600","name":"VETERANS AFFAIRS, DEPARTMENT OF"},"department":{"code":"036","name":"VETERANS AFFAIRS, DEPARTMENT OF"},"office_address":{"zip":"60141","city":"HINES","state":"IL","country":"USA"},"organization_id":"100163913","organization_type":"OFFICE"},"status":{"active":true,"latest":true,"deleted":false,"archived":false,"cancelled":false,"publication":"published","archive_date":"2027-01-15","archive_type":"auto_custom"},"history":[{"index":1,"title":"6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028","action":"publish","latest":true,"deleted":false,"archived":false,"cancelled":false,"posted_at":"2026-11-02T17:00:15.329Z","notice_type":{"code":"r","label":"Sources Sought"},"request_type":"submit","opportunity_id":"b02e003de86144c7b12c4c0b7801aab5","solicitation_number":"36E79727Q0001"}],"contacts":[{"name":"Karen Ade","role":"primary","email":"Karen.Ade@va.gov","phone":"708-786-5231","title":"Chief, Pharmaceutical Division"}],"base_type":{"code":"r","label":"Sources Sought"},"notice_id":"b02e003de86144c7b12c4c0b7801aab5","lineage_id":"b02e003de86144c7b12c4c0b7801aab5","provenance":{"detail":{"endpoints":["opportunity","resources","history"],"fetched_at":"2026-11-03T07:02:16.469652459Z"},"extract":{"url":"https://s3.amazonaws.com/falextracts/Contract%20Opportunities/datagov/ContractOpportunitiesFullCSV.csv","etag":"\"db0a8d52233632bbf6fe09ea62782db7-26\"","fetched_at":"2026-11-03T04:48:34.968936277Z","row_sha256":"6dcba2030ac5aa2700f2b81298413db421f4b0e983f9984a9fa10e69e78196cb","last_modified":"2026-11-03T04:30:46Z"},"updated_at":"2026-11-03T07:02:16.469652459Z","first_seen_at":"2026-11-03T04:48:34.968936277Z"},"description":{"html":"Department of Veterans Affairs, OALC, EPO AS7\nRequest for Information (RFI)\nSpecialty Pharmacy   Pharmaceutical Prime Vendor (PPV) 2028\n\nLimited Distribution/Closed Distribution Products (CDP) are specialty medications that are generally high-cost, low-volume items for which manufacturers restrict distribution to a small, select network of authorized distributors outside traditional wholesale channels. Specialty Pharmacy dispensed prescriptions, must have a clinical justification or regulatory requirement to restrict dispensing to specialty pharmacies. These products may require additional pharmacy-performed activities such as product-specific registration, safety checks, monitoring, or compliance with manufacturer-mandated dispensing requirements. CDPs may or may not require pass-through delivery depending on the manufacturer's distribution model.\n\nThe contractor shall ensure that all Federal Supply Schedule (FSS) items requiring specialty distribution including all those not currently/historically included or physically distributed through the Prime Vendor (PPV) are orderable by authorized ordering officers through the pharmaceutical prime vendor ordering platform. When a product requires specialty distribution, the pharmaceutical distributor shall coordinate fulfillment directly with the manufacturer-designated specialty distributor, even in cases where physical possession or shipment bypasses the pharmaceutical prime vendor. The goal is to provide seamless ordering access, accurate invoicing, and visibility into CDP transactions while maintaining compliance with manufacturer restrictions and ensuring timely, compliant delivery to VA facilities.\n\nMarket Research Questions:\n\nCould this be included in the PPV scope? What is the potential impact on pricing, performance, and competition of bringing all FSS CDPs under PPV?\n\nWould it be reasonable for any one entity to coordinate the ordering and delivery for all LDD/CDP products that are on and may be added to FSS?\n\nIs this scope currently handled within your company? If not, how would your company intend to meet this requirement OR is there another avenue you would recommend?\n\nFor all currently FSS-listed LDD/CDP products, can your company provide ordering access through the PPV (or a PPV-like) platform, regardless of distribution restrictions?\n\nAre there any FSS-listed CDPs your company historically has not been able to access due to manufacturer restrictions? If yes, please specify the nature of the barrier.\n\nWhen new CDP items are added to FSS, what onboarding timeline should VA expect for those items to become orderable through your system?\n\nDo any manufacturer agreements for FSS items explicitly prevent PPV(or PPV-like) -facilitated ordering? If so, what workarounds exist?\n\nWhat system changes are required to ensure all FSS CDPs whether physically stocked or drop-shipped are visible and orderable in the PPV (or PPV-like) ordering environment?\n\nWhat level of order visibility can be provided through your Ordering System tools for FSS CDPs fulfilled outside PPV (e.g., order acceptance, shipment status, delivery confirmation)?\n\nHow would you provide VA with consistent reporting for all FSS CDP transactions, including reconciliation between the invoice and specialty distributor fulfillment?\n\nFor FSS products subject to mandatory manufacturer programs, how does your company ensure compliance while still enabling ordering through PPV?\n\nWhat percentage of FSS-listed CDPs does your company currently distribute or coordinate?\n\nWhat system or operational investments would be required to scale your processes to support all FSS CDPs efficiently?\n\nDoes your company recommend a single PPV (or PPV-like)-based mechanism for all FSS CDPs?\n\n\nSubmission Instructions:\n\nProvide responses no later than 11AM Central November 16, 2026\nSend responses via email to Karen.Ade@va.gov\nTelephone or fax responses will not be accepted.\nInclude the following in your submission:\nCompany Name\nPoint of contact name, phone and email\nUEI and CAGE Code\nSocioeconomic designation(s), if applicable\n\n\nImportant Notes:\n\nThis announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.\nNo contract will be awarded from this notice.\nParticipation in this RFI (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.\nAll responses will be used for market research purposes only.\nThe VA may contact respondents for clarification of submitted responses.\nThe Government will not reimburse any costs associated with responding to this notice or participating in any related activities.\n\nThe VA appreciates industry's time and expertise in supporting the development of an effective PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.","text":"Department of Veterans Affairs, OALC, EPO AS7\nRequest for Information (RFI)\nSpecialty Pharmacy Pharmaceutical Prime Vendor (PPV) 2028\n\nLimited Distribution/Closed Distribution Products (CDP) are specialty medications that are generally high-cost, low-volume items for which manufacturers restrict distribution to a small, select network of authorized distributors outside traditional wholesale channels. Specialty Pharmacy dispensed prescriptions, must have a clinical justification or regulatory requirement to restrict dispensing to specialty pharmacies. These products may require additional pharmacy-performed activities such as product-specific registration, safety checks, monitoring, or compliance with manufacturer-mandated dispensing requirements. CDPs may or may not require pass-through delivery depending on the manufacturer's distribution model.\n\nThe contractor shall ensure that all Federal Supply Schedule (FSS) items requiring specialty distribution including all those not currently/historically included or physically distributed through the Prime Vendor (PPV) are orderable by authorized ordering officers through the pharmaceutical prime vendor ordering platform. When a product requires specialty distribution, the pharmaceutical distributor shall coordinate fulfillment directly with the manufacturer-designated specialty distributor, even in cases where physical possession or shipment bypasses the pharmaceutical prime vendor. The goal is to provide seamless ordering access, accurate invoicing, and visibility into CDP transactions while maintaining compliance with manufacturer restrictions and ensuring timely, compliant delivery to VA facilities.\n\nMarket Research Questions:\n\nCould this be included in the PPV scope? What is the potential impact on pricing, performance, and competition of bringing all FSS CDPs under PPV?\n\nWould it be reasonable for any one entity to coordinate the ordering and delivery for all LDD/CDP products that are on and may be added to FSS?\n\nIs this scope currently handled within your company? If not, how would your company intend to meet this requirement OR is there another avenue you would recommend?\n\nFor all currently FSS-listed LDD/CDP products, can your company provide ordering access through the PPV (or a PPV-like) platform, regardless of distribution restrictions?\n\nAre there any FSS-listed CDPs your company historically has not been able to access due to manufacturer restrictions? If yes, please specify the nature of the barrier.\n\nWhen new CDP items are added to FSS, what onboarding timeline should VA expect for those items to become orderable through your system?\n\nDo any manufacturer agreements for FSS items explicitly prevent PPV(or PPV-like) -facilitated ordering? If so, what workarounds exist?\n\nWhat system changes are required to ensure all FSS CDPs whether physically stocked or drop-shipped are visible and orderable in the PPV (or PPV-like) ordering environment?\n\nWhat level of order visibility can be provided through your Ordering System tools for FSS CDPs fulfilled outside PPV (e.g., order acceptance, shipment status, delivery confirmation)?\n\nHow would you provide VA with consistent reporting for all FSS CDP transactions, including reconciliation between the invoice and specialty distributor fulfillment?\n\nFor FSS products subject to mandatory manufacturer programs, how does your company ensure compliance while still enabling ordering through PPV?\n\nWhat percentage of FSS-listed CDPs does your company currently distribute or coordinate?\n\nWhat system or operational investments would be required to scale your processes to support all FSS CDPs efficiently?\n\nDoes your company recommend a single PPV (or PPV-like)-based mechanism for all FSS CDPs?\n\nSubmission Instructions:\n\nProvide responses no later than 11AM Central November 16, 2026\nSend responses via email to Karen.Ade@va.gov\nTelephone or fax responses will not be accepted.\nInclude the following in your submission:\nCompany Name\nPoint of contact name, phone and email\nUEI and CAGE Code\nSocioeconomic designation(s), if applicable\n\nImportant Notes:\n\nThis announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.\nNo contract will be awarded from this notice.\nParticipation in this RFI (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.\nAll responses will be used for market research purposes only.\nThe VA may contact respondents for clarification of submitted responses.\nThe Government will not reimburse any costs associated with responding to this notice or participating in any related activities.\n\nThe VA appreciates industry's time and expertise in supporting the development of an effective PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.","origin":"detail"},"notice_type":{"code":"r","label":"Sources Sought"},"schema_version":1,"solicitation_number":"36E79727Q0001","product_service_code":"6505"}],"due_at":"2026-11-16T17:00:00Z","due_date":"2026-11-16","closes_at":"2026-11-16T17:00:00Z","awardable":true,"dept_key":"d-036","dept_name":"VETERANS AFFAIRS, DEPARTMENT OF","sub_key":"s-3600","sub_name":"VETERANS AFFAIRS, DEPARTMENT OF","office_key":"o-36W797","office_name":"NAC PRIME VENDOR (36W797)","state":null,"county":null,"county_name":null,"city":null,"city_name":null,"country":null,"state_source":null,"state_evidence":"Product purchase (PSC 6505)","site_key":null,"winner_key":null,"amount":null,"linked_awards":0,"cancelled":false,"archived":false,"updated_at":"2026-11-03T07:05:06.276502Z","principal_notice_id":"b02e003de86144c7b12c4c0b7801aab5","description":{"text":"Department of Veterans Affairs, OALC, EPO AS7\nRequest for Information (RFI)\nSpecialty Pharmacy Pharmaceutical Prime Vendor (PPV) 2028\n\nLimited Distribution/Closed Distribution Products (CDP) are specialty medications that are generally high-cost, low-volume items for which manufacturers restrict distribution to a small, select network of authorized distributors outside traditional wholesale channels. Specialty Pharmacy dispensed prescriptions, must have a clinical justification or regulatory requirement to restrict dispensing to specialty pharmacies. These products may require additional pharmacy-performed activities such as product-specific registration, safety checks, monitoring, or compliance with manufacturer-mandated dispensing requirements. CDPs may or may not require pass-through delivery depending on the manufacturer's distribution model.\n\nThe contractor shall ensure that all Federal Supply Schedule (FSS) items requiring specialty distribution including all those not currently/historically included or physically distributed through the Prime Vendor (PPV) are orderable by authorized ordering officers through the pharmaceutical prime vendor ordering platform. When a product requires specialty distribution, the pharmaceutical distributor shall coordinate fulfillment directly with the manufacturer-designated specialty distributor, even in cases where physical possession or shipment bypasses the pharmaceutical prime vendor. The goal is to provide seamless ordering access, accurate invoicing, and visibility into CDP transactions while maintaining compliance with manufacturer restrictions and ensuring timely, compliant delivery to VA facilities.\n\nMarket Research Questions:\n\nCould this be included in the PPV scope? What is the potential impact on pricing, performance, and competition of bringing all FSS CDPs under PPV?\n\nWould it be reasonable for any one entity to coordinate the ordering and delivery for all LDD/CDP products that are on and may be added to FSS?\n\nIs this scope currently handled within your company? If not, how would your company intend to meet this requirement OR is there another avenue you would recommend?\n\nFor all currently FSS-listed LDD/CDP products, can your company provide ordering access through the PPV (or a PPV-like) platform, regardless of distribution restrictions?\n\nAre there any FSS-listed CDPs your company historically has not been able to access due to manufacturer restrictions? If yes, please specify the nature of the barrier.\n\nWhen new CDP items are added to FSS, what onboarding timeline should VA expect for those items to become orderable through your system?\n\nDo any manufacturer agreements for FSS items explicitly prevent PPV(or PPV-like) -facilitated ordering? If so, what workarounds exist?\n\nWhat system changes are required to ensure all FSS CDPs whether physically stocked or drop-shipped are visible and orderable in the PPV (or PPV-like) ordering environment?\n\nWhat level of order visibility can be provided through your Ordering System tools for FSS CDPs fulfilled outside PPV (e.g., order acceptance, shipment status, delivery confirmation)?\n\nHow would you provide VA with consistent reporting for all FSS CDP transactions, including reconciliation between the invoice and specialty distributor fulfillment?\n\nFor FSS products subject to mandatory manufacturer programs, how does your company ensure compliance while still enabling ordering through PPV?\n\nWhat percentage of FSS-listed CDPs does your company currently distribute or coordinate?\n\nWhat system or operational investments would be required to scale your processes to support all FSS CDPs efficiently?\n\nDoes your company recommend a single PPV (or PPV-like)-based mechanism for all FSS CDPs?\n\nSubmission Instructions:\n\nProvide responses no later than 11AM Central November 16, 2026\nSend responses via email to Karen.Ade@va.gov\nTelephone or fax responses will not be accepted.\nInclude the following in your submission:\nCompany Name\nPoint of contact name, phone and email\nUEI and CAGE Code\nSocioeconomic designation(s), if applicable\n\nImportant Notes:\n\nThis announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.\nNo contract will be awarded from this notice.\nParticipation in this RFI (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.\nAll responses will be used for market research purposes only.\nThe VA may contact respondents for clarification of submitted responses.\nThe Government will not reimburse any costs associated with responding to this notice or participating in any related activities.\n\nThe VA appreciates industry's time and expertise in supporting the development of an effective PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.","html":"Department of Veterans Affairs, OALC, EPO AS7\nRequest for Information (RFI)\nSpecialty Pharmacy   Pharmaceutical Prime Vendor (PPV) 2028\n\nLimited Distribution/Closed Distribution Products (CDP) are specialty medications that are generally high-cost, low-volume items for which manufacturers restrict distribution to a small, select network of authorized distributors outside traditional wholesale channels. Specialty Pharmacy dispensed prescriptions, must have a clinical justification or regulatory requirement to restrict dispensing to specialty pharmacies. These products may require additional pharmacy-performed activities such as product-specific registration, safety checks, monitoring, or compliance with manufacturer-mandated dispensing requirements. CDPs may or may not require pass-through delivery depending on the manufacturer's distribution model.\n\nThe contractor shall ensure that all Federal Supply Schedule (FSS) items requiring specialty distribution including all those not currently/historically included or physically distributed through the Prime Vendor (PPV) are orderable by authorized ordering officers through the pharmaceutical prime vendor ordering platform. When a product requires specialty distribution, the pharmaceutical distributor shall coordinate fulfillment directly with the manufacturer-designated specialty distributor, even in cases where physical possession or shipment bypasses the pharmaceutical prime vendor. The goal is to provide seamless ordering access, accurate invoicing, and visibility into CDP transactions while maintaining compliance with manufacturer restrictions and ensuring timely, compliant delivery to VA facilities.\n\nMarket Research Questions:\n\nCould this be included in the PPV scope? What is the potential impact on pricing, performance, and competition of bringing all FSS CDPs under PPV?\n\nWould it be reasonable for any one entity to coordinate the ordering and delivery for all LDD/CDP products that are on and may be added to FSS?\n\nIs this scope currently handled within your company? If not, how would your company intend to meet this requirement OR is there another avenue you would recommend?\n\nFor all currently FSS-listed LDD/CDP products, can your company provide ordering access through the PPV (or a PPV-like) platform, regardless of distribution restrictions?\n\nAre there any FSS-listed CDPs your company historically has not been able to access due to manufacturer restrictions? If yes, please specify the nature of the barrier.\n\nWhen new CDP items are added to FSS, what onboarding timeline should VA expect for those items to become orderable through your system?\n\nDo any manufacturer agreements for FSS items explicitly prevent PPV(or PPV-like) -facilitated ordering? If so, what workarounds exist?\n\nWhat system changes are required to ensure all FSS CDPs whether physically stocked or drop-shipped are visible and orderable in the PPV (or PPV-like) ordering environment?\n\nWhat level of order visibility can be provided through your Ordering System tools for FSS CDPs fulfilled outside PPV (e.g., order acceptance, shipment status, delivery confirmation)?\n\nHow would you provide VA with consistent reporting for all FSS CDP transactions, including reconciliation between the invoice and specialty distributor fulfillment?\n\nFor FSS products subject to mandatory manufacturer programs, how does your company ensure compliance while still enabling ordering through PPV?\n\nWhat percentage of FSS-listed CDPs does your company currently distribute or coordinate?\n\nWhat system or operational investments would be required to scale your processes to support all FSS CDPs efficiently?\n\nDoes your company recommend a single PPV (or PPV-like)-based mechanism for all FSS CDPs?\n\n\nSubmission Instructions:\n\nProvide responses no later than 11AM Central November 16, 2026\nSend responses via email to Karen.Ade@va.gov\nTelephone or fax responses will not be accepted.\nInclude the following in your submission:\nCompany Name\nPoint of contact name, phone and email\nUEI and CAGE Code\nSocioeconomic designation(s), if applicable\n\n\nImportant Notes:\n\nThis announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.\nNo contract will be awarded from this notice.\nParticipation in this RFI (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.\nAll responses will be used for market research purposes only.\nThe VA may contact respondents for clarification of submitted responses.\nThe Government will not reimburse any costs associated with responding to this notice or participating in any related activities.\n\nThe VA appreciates industry's time and expertise in supporting the development of an effective PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.","origin":"detail"},"contacts":[{"name":"Karen Ade","role":"primary","email":"Karen.Ade@va.gov","phone":"708-786-5231","title":"Chief, Pharmaceutical Division"}],"place_of_performance":null,"office_address":{"zip":"60141","city":"HINES","state":"IL","country":"USA"},"naics_codes":["325412"],"award":{"awardee":{}},"attachments":[{"resource_id":"d3f66ba42d7e4a6cb30c5380d7d030b4","name":"36E79727Q0001_1.docx","kind":"file","mime_type":".docx","size_bytes":18247,"posted_at":"2026-11-02T17:00:15.329Z","export_controlled":false,"sha256":null,"url":"https://sam.gov/api/prod/opps/v3/opportunities/resources/files/d3f66ba42d7e4a6cb30c5380d7d030b4/download","mirrored":false}],"awards":[],"related":[],"similar_open":[{"key":"36E79727R0007","latest_notice_id":"6ee0c937156749b0a15d03635aff62f0","title":"6505--Sacubitril/Valsartan Tablets (VA-27-00014055)","solicitation_number":"36E79727R0007","notice_type":"p","first_type":"p","first_posted":"2026-10-22","last_posted":"2026-10-22","notices":1,"due_at":"2026-11-03T20:30:00Z","due_date":"2026-11-03","closes_at":"2026-11-03T20:30:00Z","awardable":true,"open":true,"removed":false,"dept_key":"d-036","dept_name":"VETERANS AFFAIRS, DEPARTMENT OF","sub_key":"s-3600","sub_name":"VETERANS AFFAIRS, DEPARTMENT OF","office_key":"o-36E797","office_name":"NAC PHARMACEUTICALS (36E797)","naics":"325412","psc":"6505","set_aside":null,"state":null,"county":null,"county_name":null,"city":null,"city_name":null,"country":null,"place_scope":"nationwide","state_source":null,"state_evidence":"Product purchase (PSC 6505)","site":null,"site_key":null,"winner":null,"winner_key":null,"amount":null,"linked_awards":0,"cancelled":false,"archived":false,"removed_at":null,"updated_at":"2026-10-23T03:46:32.604852Z"},{"key":"SPE2D226R0013","latest_notice_id":"37bf5530c25b4155a601effe7b1ef8f4","title":"Methylphenidate ER","solicitation_number":"SPE2D226R0013","notice_type":"o","first_type":"p","first_posted":"2026-07-08","last_posted":"2026-10-21","notices":4,"due_at":"2026-11-06T20:00:00Z","due_date":"2026-11-06","closes_at":"2026-11-06T20:00:00Z","awardable":true,"open":true,"removed":false,"dept_key":"d-097","dept_name":"DEPT OF DEFENSE","sub_key":"s-97AS","sub_name":"DEFENSE LOGISTICS AGENCY","office_key":"o-SPE2D2","office_name":"DLA TROOP SUPPORT","naics":"325412","psc":"6505","set_aside":null,"state":null,"county":null,"county_name":null,"city":null,"city_name":null,"country":null,"place_scope":"nationwide","state_source":null,"state_evidence":"Product purchase (PSC 6505)","site":null,"site_key":null,"winner":null,"winner_key":null,"amount":null,"linked_awards":0,"cancelled":false,"archived":false,"removed_at":null,"updated_at":"2026-10-22T04:09:15.685315Z"},{"key":"36C26227Q0083","latest_notice_id":"d13b067a4252475d95d1ebb22b7c1ae5","title":"6505--FY27 Lenalidomide BPA","solicitation_number":"36C26227Q0083","notice_type":"r","first_type":"r","first_posted":"2026-10-30","last_posted":"2026-10-30","notices":1,"due_at":"2026-11-12T18:00:00Z","due_date":"2026-11-12","closes_at":"2026-11-12T18:00:00Z","awardable":true,"open":true,"removed":false,"dept_key":"d-036","dept_name":"VETERANS AFFAIRS, DEPARTMENT OF","sub_key":"s-3600","sub_name":"VETERANS AFFAIRS, DEPARTMENT OF","office_key":"o-36C262","office_name":"262-NETWORK CONTRACT OFFICE 22 (36C262)","naics":"325412","psc":"6505","set_aside":null,"state":null,"county":null,"county_name":null,"city":null,"city_name":null,"country":null,"place_scope":"nationwide","state_source":null,"state_evidence":"Product purchase (PSC 6505)","site":null,"site_key":null,"winner":null,"winner_key":null,"amount":null,"linked_awards":0,"cancelled":false,"archived":false,"removed_at":null,"updated_at":"2026-10-31T03:50:03.904859Z"}],"similar_open_total":9}